Ondine Biomedical Inc (OBI) NPV

- Add to watchlist
- Create an alert
- This stock can be held in a




15.25p
15.50p
18.25p
£76.46 million
15.30p
14.63p
5.63p
n/a
0.05p (0.33%) Previous:
0.05p
49,091
n/a
20,000
Performance
1 week 1W | 0.33% | 1 year 1Y | 140% |
---|---|---|---|
1 month 1M | 5.85% | 2 years 2Y | 53% |
3 months 3M | 45.71% | 3 years 3Y | 60.26% |
6 months 6M | 56.92% | 5 years 5Y | n/a |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 1.20 | 0.64 |
Profit before tax ($m) | (14.41) | (19.37) |
Adjusted EPS (¢): | (7.00) | (10.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Ondine to present Steriwave analysis at Geneva conference
3 September 2025 12:52
-
Ondine to pilot Steriwave at Mexico City hospital
13 August 2025 14:50
-
Ondine completes landmark Steriwave study
21 July 2025 12:30
-
Steriwave proven to be effective against C Auris
15 September 2025 10:44
-
Grant of Options
12 September 2025 07:00
-
Steriwave Featured on CNBC’s Worldwide Exchange
10 September 2025 07:00
Annual & interim reports
Annual & interim reports are not available for this stock.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.